Brokerages Set Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Price Target at $6.75

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has received a consensus rating of “Hold” from the nine brokerages that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $6.75.

ZNTL has been the topic of a number of research reports. Rodman & Renshaw began coverage on Zentalis Pharmaceuticals in a research note on Thursday, July 23rd. They set a “buy” rating and a $11.00 price target on the stock. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Friday, May 22nd. Mizuho began coverage on Zentalis Pharmaceuticals in a report on Friday, July 17th. They set an “outperform” rating and a $8.00 price objective for the company. Wall Street Zen lowered Zentalis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research report on Monday, July 6th.

Institutional Trading of Zentalis Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Sivia Capital Partners LLC bought a new position in shares of Zentalis Pharmaceuticals in the fourth quarter valued at $27,000. CTC Alternative Strategies Ltd. bought a new stake in shares of Zentalis Pharmaceuticals during the first quarter worth about $29,000. Qube Research & Technologies Ltd bought a new stake in shares of Zentalis Pharmaceuticals during the second quarter worth about $37,000. Voleon Capital Management LP bought a new stake in shares of Zentalis Pharmaceuticals during the third quarter worth about $41,000. Finally, State of Wyoming acquired a new stake in shares of Zentalis Pharmaceuticals in the 1st quarter worth about $67,000.

Zentalis Pharmaceuticals Trading Down 0.5%

ZNTL opened at $3.68 on Friday. The company has a fifty day moving average price of $4.34 and a two-hundred day moving average price of $3.65. Zentalis Pharmaceuticals has a 1-year low of $1.21 and a 1-year high of $6.95. The company has a market cap of $263.75 million, a P/E ratio of -1.89 and a beta of 1.92.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.10). On average, research analysts forecast that Zentalis Pharmaceuticals will post -2.14 EPS for the current fiscal year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.